Castleman’s Disease

Chapter
First Online:

Abstract

Castleman’s disease (CD) is an uncommon lymphoproliferative disorder. Its etiology is related to HHV-8 infection, with immunocompromised patients as the most vulnerable population. Patients with the multicentric variant of CD require systemic treatment but the disease course often includes severe complications or evolution into malignant neoplasm. PET with 18F-FDG is useful in the early detection of metabolically active CD lesions, in assessing disease extent, guiding biopsy, discriminating disease persistence/recurrence from post-therapeutic changes, and monitoring the response to treatment. The value of PET/CT in the differential diagnosis between CD and malignancies such as lymphoma requires further study.

Keywords

Lymphoproliferative Disorder Pathological Lymph Node Multicentric Variant Monitoring Treatment Response Peripheral Lymphadenopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Farruggia P, Trizzino A, Scibetta N et al (2011) Castleman’s disease in childhood: report of three cases and review of the literature. Ital J Pediatr 37:50PubMedCrossRefGoogle Scholar
  2. 2.
    Lin CY, Huang TC (2011) Cervical posterior triangle Castleman’s disease in a child – case report & literature review. Chang Gung Med J 34:435–439PubMedGoogle Scholar
  3. 3.
    Park JB, Hwang JH, Kim H et al (2007) Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant. Korean J Intern Med 22:113–117PubMedCrossRefGoogle Scholar
  4. 4.
    Van Aalderen MC, Brinkman K, Van Den Berk GE et al (2010) Vinblastine, rituximab and HART, treatment of an HIV-positive patient with multicentric Castleman’s disease. Neth J Med 68:87–90PubMedGoogle Scholar
  5. 5.
    Toita N, Kawamura N, Hatano N et al (2009) A 5-year-old boy with unicentric Castleman disease affecting the mesentery: utility of serum IL-6 level and (18)F-FDG PET for diagnosis. J Pediatr Hematol Oncol 31:693–695PubMedCrossRefGoogle Scholar
  6. 6.
    Arlet JB, Hermine O, Darnige L et al (2010) Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 126:1608–1612CrossRefGoogle Scholar
  7. 7.
    Enomoto K, Nakamichi I, Hamada K et al (2007) Unicentric and multicentric Castleman’s disease. Br J Radiol 80:24–26CrossRefGoogle Scholar
  8. 8.
    Liu QY, Chen MC, Chen XH et al (2011) Imaging characteristics of abdominal tumor in association with paraneoplastic pemphigus. Eur J Dermatol 21:83–88PubMedGoogle Scholar
  9. 9.
    Akosman C, Selcuk NA, Ordu C, Ercan S, Ekici ID, Oyan B (2011) Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment. Cancer Imaging 11:52–55PubMedCrossRefGoogle Scholar
  10. 10.
    Bertagna F, Biasiotto G, Rodella R et al (2010) 18F-Fluorodeoxyglucose positron emission tomography/computed tomography findings in a patient with human immunodeficiency virus-associated Castleman’s disease and Kaposi sarcoma, disorders associated with human herpes virus 8 infection. Jpn J Radiol 28:231–234PubMedCrossRefGoogle Scholar
  11. 11.
    Barker R, Kazmi F, Stebbing J et al (2009) FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging 36:648–652PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.Nuclear Medicine Unit, Department of Radiological Sciences, Policlinico Gaetano Martino HospitalUniversity of MessinaMessinaItaly
  2. 2.Department of Nuclear MedicinePositron Emission Tomography Center IRMET S.p.A., Euromedic Inc.TurinItaly
  3. 3.Institute of Cognitive Sciences and TechnologiesNational Research CouncilRomeItaly

Personalised recommendations